Disease · MONDO_0005806
hypopharynx cancer
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. hypopharynx cancer. Diseases, record MONDO_0005806. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005806
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
hypopharyngeal cancer, hypopharynx pharynx cancer, hypural pharynx cancer, malignant hypopharyngeal neoplasm, malignant hypopharyngeal tumor, malignant hypopharyngeal tumour, malignant neoplasm of hypopharynx, malignant neoplasm of ill-defined sites within the lip and oral cavity, malignant neoplasm of other specified hypopharyngeal site, malignant neoplasm of other specified sites of hypopharynx, malignant neoplasm of posterior hypopharyngeal wall, malignant neoplasm of posterior wall of hypopharynx, malignant neoplasm of the hypopharynx, malignant tumor of hypopharynx, malignant tumor of posterior wall of hypopharynx, malignant tumor of the hypopharynx, malignant tumour of hypopharynx, malignant tumour of posterior wall of hypopharynx, malignant tumour of the hypopharynx, pharynx cancer of hypopharynx
- Open Targets
Drugs14
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| DOCETAXEL | CHEMBL3545252 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| CETUXIMAB | CHEMBL1201577 | Antibody | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ADEBRELIMAB | CHEMBL4297828 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NIVOLUMAB | CHEMBL2108738 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PEMBROLIZUMAB | CHEMBL3137343 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PLATINUM | CHEMBL1235478 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 14
See all 14 drugsTargets23
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 10 of 23
See all 23 targetsTrials15
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03894891 | Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer | Phase 2 | 6 | 2023-12-20 | Head and Neck Cancer | CISPLATIN, DOCETAXEL, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00002839 | Combination Chemotherapy Plus Radiation Therapy To Preserve the Larynx in Patients With Cancer of the Hypopharynx or Larynx | Phase 3 | 564 | Head and Neck Cancer | CISPLATIN, FLUOROURACIL | Its record names the disease | ClinicalTrials.gov | |
| NCT03340896 | Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT | Phase 3 | 256 | Head and Neck Squamous Cell Carcinoma | CISPLATIN, DOCETAXEL, FLUOROURACIL | Its record names the disease | ClinicalTrials.gov | |
| NCT00534729 | Organ Preservation: Weekly Carboplatin & Taxol w/Concurrent RT for Locally Advanced Laryngeal & Hypopharyngeal CA | Not applicable | 200 | Laryngeal Neoplasms, Hypopharyngeal Neoplasms | CARBOPLATIN, PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT00508664 | Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA) | Phase 2 | 180 | Squamous Cell Carcinoma of the Hypopharynx, Larynx Carcinoma | CETUXIMAB, CISPLATIN, DOCETAXEL, FLUOROURACIL | Its record names the disease | ClinicalTrials.gov | |
| NCT05551767 | Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer | Phase 2 | 120 | Neck Cancer | PEMBROLIZUMAB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00002735 | SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue | Phase 2 | 68 | Head and Neck Cancer | CISPLATIN, FLUOROURACIL | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov | |
| NCT04883281 | A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer | Phase 2 | 50 | Head and Neck Cancer | CARBOPLATIN, CETUXIMAB, CISPLATIN, PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT06554028 | Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer | Phase 2 | 46 | Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms | TISLELIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT07137039 | Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen | Phase 2 | 34 | Locally Advanced Hypopharyngeal Cancer | ADEBRELIMAB, CISPLATIN, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 15
See all 15 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials6
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005806
GET https://conductscience.org/api/diseases/v1/MONDO_0005806/targets?page=2